Heterocyclic compounds and uses thereof
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
T is —NHC(O)— or —C(O)NH—;
W is CH or N;
each of R a , R b , R c , and R d is independently selected from R, OR, or halogen;
each R is independently hydrogen, lower alkyl, or lower haloalkyl;
R 1 is -L-Y, wherein:
L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by cyclopropylene, —NRC(O)—, —C(O)NR—, —S—, —S(O)—, —SO 2 —, —C(═S)—, —C(═NR)—, —N═N—, or —C(═N 2 )—; and one or two additional methylene units of L are optionally and independently replaced by —O—, —N(R)—, or —C(O)—; or
L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two additional methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —S—, —S(O)—, —SO 2 —, —C(═S)—, —C(═NR)—, —O—, —N(R)—, or —C(O)—; or
L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one or two additional methylene units of L are independently replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO 2 —, or —SO 2 N(R)—; or
L is a bivalent C 1-8 , straight or branched, alkylene chain, wherein at least one methylene unit of L is replaced by —C(═N 2 )—, and one or two additional methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —S—, —S(O)—, —SO 2 —, —C(═S)—, —C(═NR)—, —O—, —N(R)—, or —C(O)—; and
Y is hydrogen, C 1-6 aliphatic optionally substituted with oxo, halogen, or CN, or a 3-10 membered monocyclic or bicyclic, saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with 1-4 groups independently selected from -Q-Z, oxo, halogen, CN, or C 1-6 aliphatic, wherein:
Q is a covalent bond or a bivalent C 1-6 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one or two methylene units of Q are optionally and independently replaced by —NR—, —NRC(O)—, —C(O)NR—, —S—, —O—, —C(O)—, —SO—, or —SO 2 —; and
Z is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, or CN;
R 2 is selected from R, halogen, —N(R)C(O)OR, or 1-imidazoyl substituted with R, or:
R 1 and R 2 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted -L-Y and 0-3 groups independently selected from oxo, halogen, CN, or C 1-6 aliphatic; and
R 3 is selected from hydrogen, lower alkyl, or halogen.
2. The compound according to claim 1 , wherein said compound is of formula II-a or III-a:
or a pharmaceutically acceptable salt thereof, wherein:
L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one double bond and at least one methylene unit of L is replaced by cyclopropylene, —NRC(O)—, —C(O)NR—, —S—, —S(O)—, —SO 2 —, —C(═S)—, —C(═NR)—, —N═N—, or —C(═N 2 )—, and one or two additional methylene units of L are optionally and independently replaced by —O—, —N(R)—, or —C(O)—; and
R 2 is selected from R, halogen, —N(R)C(O)OR, or 1-imidazoyl substituted with R.
3. The compound according to claim 2 , wherein:
Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, or CN; and
R 3 is lower alkyl.
4. The compound according to claim 3 , wherein L is —NHC(O)CH═CH—, —NHC(O)CH═CHCH 2 N(CH 3 )—, —NHC(O)CH═CHCH 2 O—, —CH 2 NHC(O)CH═CH—, —NHSO 2 CH═CH—, —NHSO 2 CH═CHCH 2 —, —NHC(O)(C═N 2 )—, —NHC(O)(C═N 2 )C(O)—, or —NHC(O)C(═CH 2 )CH 2 —.
5. The compound according to claim 2 , wherein L has at least one alkylidenyl double bond.
6. The compound according to claim 5 , wherein R 2 is hydrogen, —CF 3 , or 1-imidazoyl substituted with R.
7. The compound according to claim 1 , wherein:
L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein L has at least one triple bond and one or two additional methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —S—, —S(O)—, —SO 2 —, —C(═S)—, —C(═NR)—, —O—, —N(R)—, or —C(O)—.
8. The compound according to claim 7 , wherein:
L is —C≡C—, —C≡CCH 2 N(isopropyl)-, —NHC(O)C≡CCH 2 CH 2 —, —CH 2 —C≡C—CH 2 —, or —C≡CCH 2 O—; and
Y is hydrogen, C 1-6 aliphatic optionally substituted with oxo, halogen, or CN, phenyl, pyridyl, or an optionally substituted saturated 3-6 membered monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is substituted with at 1-4 groups independently selected from -Q-Z, oxo, halogen, CN, or C 1-6 aliphatic.
9. The compound according to claim 1 , wherein:
L is a bivalent C 2-8 straight or branched, hydrocarbon chain wherein one methylene unit of L is replaced by cyclopropylene and one or two additional methylene units of L are independently replaced by —C(O)—, —NRC(O)—, —C(O)NR—, —N(R)SO 2 —, or —SO 2 N(R)—.
10. The compound according to claim 9 , wherein:
L is —NHC(O)-cyclopropylene-SO 2 — and —NHC(O)-cyclopropylene-; and
Y is hydrogen, CN, or C 1-6 aliphatic optionally substituted with oxo, halogen, or CN.
11. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
T is —NHC(O)— or —C(O)NH—;
W is CH or N;
each of R a , R b , R c , and R d is independently selected from R, OR, or halogen;
each R is independently hydrogen, lower alkyl, or lower haloalkyl;
R 1 is -L-Y, wherein:
L is a covalent bond or a bivalent C 1-8 saturated or unsaturated, straight or branched, hydrocarbon chain, wherein one, two, or three methylene units of L are optionally and independently replaced by —NR—, —N(R)C(O)—, —C(O)N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —SO—, —SO 2 —, or —C(═S)—;
Y is selected from:
R 2 is selected from R, halogen, —N(R)C(O)OR, or 1-imidazoyl substituted with R, or:
R 1 and R 2 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with -L-Y and 0-3 groups independently selected from oxo, halogen, CN, or C 1-6 aliphatic; and
R 3 is selected from hydrogen, lower alkyl, or halogen.
12. The compound according to claim 11 , wherein L is a covalent bond, —CH 2 —, —NH—, —CH 2 NH—, —NHCH 2 —, —NHC(O)—, —NHC(O)CH 2 OC(O)—, —CH 2 NHC(O)—, —NHSO 2 —, —NHSO 2 CH 2 —, —NHC(O)CH 2 OC(O)—, or —SO 2 NH—.
13. The compound according to claim 1 , wherein:
L is a bivalent C 1-8 , straight or branched, alkylene chain, wherein at least one methylene unit of L is replaced by —C(═N 2 )—, and one or two additional methylene units of L are optionally and independently replaced by —NRC(O)—, —C(O)NR—, —S—, —S(O)—, —SO 2 —, —C(═S)—, —C(═NR)—, —O—, —N(R)—, or —C(O)—.
14. The compound according to claim 13 , wherein:
L is —NHC(O)(C═N 2 )— or —NHC(O)(C═N 2 )C(O)—; and
Y is hydrogen or C 1-6 aliphatic optionally substituted with oxo, halogen, or CN, or an optionally substituted saturated 3-6 membered monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl or pyridyl.
15. The compound according to claim 1 , wherein said compound is of formula II-a or III-a:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 and R 2 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, or aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is substituted with -L-Y and the ring is further substituted with 0-3 groups independently selected from oxo, halogen, CN, or C 1-6 aliphatic.
16. The compound according to claim 15 , wherein R 1 and R 2 are taken together with their intervening atoms to form, together with the phenyl ring fused thereto, a naphthyl, tetrahydroquinoline, indoline, isoindoline, 1H-indole, or tetrahydroisoquinoline ring.
17. The compound according to claim 15 , wherein -L-Y is —NHC(O)CH═CH 2 or —C(O)CH═CH 2 .
18. The compound according to claim 1 , wherein said compound is selected from the group consisting of:
19. The compound according to claim 1 , wherein said compound is selected from the group consisting of:
20. The compound according to claim 1 , wherein said compound is of the following structure:
21. The compound according to claim 1 , wherein said compound is of the following structure:
22. The compound according to claim 1 , wherein said compound is of the following structure:
23. The compound according to claim 1 , wherein said compound is of the following structure:
24. The compound according to claim 11 , wherein said compound is of the following structure:
25. The compound according to claim 1 , wherein said compound is of the following structure:
26. A composition comprising a compound according to claim 1 , and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
27. The composition according to claim 26 , in combination with an additional therapeutic agent.
28. The composition according to claim 27 , wherein the additional therapeutic agent is a chemotherapeutic agent.
29. The compound according to claim 11 , wherein said compound is selected from the group consisting of:
30. The compound according to claim 11 , wherein said compound is selected from the group consisting of:
31. A compound selected from the group consisting of: